Magnesium glycinate offers a promising and well-tolerated option for migraine management. Its high bioavailability and gentle effect on the digestive system make it a suitable choice for many individuals suffering from migraine.
The FDA has just approved fremanezumab (Ajovy) for the preventive treatment of episodic migraine in children and adolescents ages 6–17.
Alexander Feoktistov, MD, PhD, director of the Synergy Integrative Headache Clinic, addressed the unique aspects of cluster headaches as well as other TAC, or trigeminal autonomic cephalalgia at the American Academy of Pain Medicine’s 2018 annual meeting.
